Cure8 news brief
Long-term maintenance of clinical and endoscopic remission is a key goal in Crohn’s disease care. Positive two-year data and FDA approval may affect treatment options for adults, including people who previously failed other biologics.
Adults with moderately to severely active Crohn's disease, especially those considering or using biologic therapies; gastroenterologists and IBD clinicians; clinical researchers and people tracking new IBD drug approvals.
These results describe two-year outcomes from participants who continued mirikizumab after initial response in the VIVID-1/VIVID-2 program. Large proportions reportedly maintained clinical remission and endoscopic response at two years; some participants who were not in remission at one year improved during the second year.
The piece highlights the drug’s mechanism (IL-23p19 targeting) and notes the therapy’s recent FDA approval for adults with moderately to severely active Crohn’s disease. Practical points: this is a news report summarizing trial results and regulatory status rather than a full peer-reviewed publication.
It does not provide detailed study methods, subgroup analyses, or individual risk information.
This article is a media summary of company-reported trial results (Phase III VIVID program) and mentions FDA approval. It is not a full scientific paper—details on study design, statistical analyses, or long-term safety specifics are not provided here. For treatment decisions, consult detailed trial publications and your clinician.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing...
This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care...
This trial suggests a new IL‑23 inhibitor, mirikizumab, may be an effective and safe treatment option for adults with moderate-to-severe Crohn's disease who have not responded to prior therapies. Positive phase 3 results...
